{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:09:16Z","timestamp":1769832556958,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00417-021-05499-0","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:00:52Z","timestamp":1638342052000},"page":"1915-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity"],"prefix":"10.1007","volume":"260","author":[{"given":"Amir","family":"Sternfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Rossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping D.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-1394","authenticated-orcid":false,"given":"Hawke H.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"5499_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","volume":"10","author":"J Chen","year":"2007","unstructured":"Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133\u2013140. https:\/\/doi.org\/10.1007\/s10456-007-9066-0","journal-title":"Angiogenesis"},{"key":"5499_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME (2015) Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology 122:200\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.050","journal-title":"Ophthalmology"},{"key":"5499_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity Preliminary results. Arch Ophthalmol 106:471\u2013479. https:\/\/doi.org\/10.1001\/archopht.1988.01060130517027","journal-title":"Arch Ophthalmol"},{"key":"5499_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"key":"5499_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ et al (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"5499_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","volume":"124","author":"DK VanderVeen","year":"2017","unstructured":"VanderVeen DK, Melia M, Yang MB et al (2017) Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 124:619\u2013633. https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.025","journal-title":"Ophthalmology"},{"key":"5499_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bjophthalmol-2016-308375","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E et al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101:365\u2013370. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308375","journal-title":"Br J Ophthalmol"},{"key":"5499_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"key":"5499_CR9","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jcjo.2017.09.028","volume":"53","author":"S Agarwal-Sinha","year":"2018","unstructured":"Agarwal-Sinha S, Guevara JG, Amin SM (2018) Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity. Can J Ophthalmol 53:e99\u2013e103. https:\/\/doi.org\/10.1016\/j.jcjo.2017.09.028","journal-title":"Can J Ophthalmol"},{"key":"5499_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol"},{"key":"5499_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J et al (2017) Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 37:710\u2013717. https:\/\/doi.org\/10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"5499_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","volume":"198","author":"TA Chen","year":"2019","unstructured":"Chen TA, Shields RA, Bodnar ZH et al (2019) A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol 198:63\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039","journal-title":"Am J Ophthalmol"},{"key":"5499_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M et al (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38:764\u2013772. https:\/\/doi.org\/10.1097\/IAE.0000000000001581","journal-title":"Retina"},{"key":"5499_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","volume":"18","author":"A Henaine-Berra","year":"2014","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H et al (2014) Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS 18:120\u2013123. https:\/\/doi.org\/10.1016\/j.jaapos.2013.12.009","journal-title":"J AAPOS"},{"key":"5499_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC et al (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507\u2013512. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109","journal-title":"Br J Ophthalmol"},{"key":"5499_CR16","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F et al (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","journal-title":"Ophthalmology"},{"key":"5499_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3928\/23258160-20170301-10","volume":"48","author":"AR Hajrasouliha","year":"2017","unstructured":"Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ et al (2017) Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48:255\u2013259. https:\/\/doi.org\/10.3928\/23258160-20170301-10","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"5499_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","volume":"3","author":"SA Mansukhani","year":"2019","unstructured":"Mansukhani SA, Hutchinson AK, Neustein R et al (2019) Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression. Ophthalmol Retina 3:436\u2013443. https:\/\/doi.org\/10.1016\/j.oret.2019.01.016","journal-title":"Ophthalmol Retina"},{"key":"5499_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ et al (2013) Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS 17:323\u2013325. https:\/\/doi.org\/10.1016\/j.jaapos.2013.01.004","journal-title":"J AAPOS"},{"key":"5499_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ et al (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47:280\u2013283. https:\/\/doi.org\/10.3928\/23258160-20160229-12","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"5499_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1399-6576.2006.01068.x","volume":"50","author":"S Walther-Larsen","year":"2006","unstructured":"Walther-Larsen S, Rasmussen LS (2006) The former preterm infant and risk of post-operative apnoea: recommendations for management. Acta Anaesthesiol Scand 50:888\u2013893. https:\/\/doi.org\/10.1111\/j.1399-6576.2006.01068.x","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05499-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05499-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05499-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T10:04:27Z","timestamp":1651485867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05499-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5499"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05499-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ann and Robert H. Lurie Children\u2019s Hospital of Chicago Institutional Review Board (IRB) reviewed and approved the protocol via expedited review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The IRB waived the requirement of obtaining informed consent in accordance with 45 CFR 46.116 (d).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}